Levothyroxine Sodium
FDA recalls
25 rows
| Date | Company and reason |
|---|---|
| Sep 28, 2026 | Pfizer Subpotent Drug: confirmed out-of-specification (OOS) assay during stability testing. |
| Aug 5, 2026 | Accord Healthcare, Inc. Subpotent Drug |
| Jul 12, 2026 | Major Pharmaceuticals Subpotent Drug |
| Jun 7, 2026 | Accord Healthcare, Inc. Subpotent Drug |
| Feb 25, 2026 | Macleods Pharma USA, Inc Subpotent Drug |
| Sep 15, 2025 | Accord Healthcare, Inc. Subpotent: During long term stability testing of Levothyroxine Sodium Tablets USP for 88 mcg, the assay content was observed below the approved specification range. |
| Jul 28, 2025 | Pfizer Subpotent drug |
| Jun 19, 2025 | Accord Healthcare, Inc. Subpotent Drug: Assay below the approved specification |
| May 28, 2025 | Macleods Pharmaceuticals Ltd Presence of a foreign substance: black hair found embedded in tablet. |
| Apr 9, 2025 | Accord Healthcare, Inc. Subpotent |
| Mar 6, 2025 | Mylan Institutional, Inc. Super-Potent Drug: Out of specification potency results were obtained. |
| Dec 19, 2024 | Lupin Pharmaceuticals Inc. Failed Impurities/Degradation Specifications: Out of specifications result observed in the drug substance for impurity test during 3-month long term stability study. |
| Nov 18, 2024 | Mylan Institutional, Inc. Subpotent and Superpotent Drug |
| Nov 7, 2024 | Accord Healthcare, Inc. Subpotent drug |
| Oct 16, 2023 | AbbVie Inc. Labeling: Wrong Barcode- One of every forty unit dose blister will contain incorrect barcode information that causes a 125mcg unit dose is scanned as 200mcg unit dose. |
| Jan 29, 2023 | Ibsa Pharma Inc Subpotent Drug |
| Mar 14, 2021 | Cardinal Health Inc. CGMP Deviations: Intermittent exposure to temperature excursion during storage. |
| Dec 5, 2018 | Pfizer Inc. Superpotent Drug. |
| Nov 6, 2016 | Pfizer Inc. Superpotent |
| Apr 29, 2013 | King Legacy, A Wholly Owned Subsidiary of Pfizer Subpotent Drug: The products were below specification for potency at the expiry stability point. |
| Mar 27, 2013 | Pfizer Inc. Chemical contamination: emission of strong odor after package was opened |
| Mar 27, 2013 | Pfizer Inc. Chemical contamination: emission of strong odor after package was opened.. |
| Mar 27, 2013 | Pfizer Inc. Chemical contamination: emission of strong odor after package was opened. |
| Dec 3, 2012 | Abbott Laboratories Labeling: Error on Declared Strength. Product labeled to contain 150 mcg tablets actually contained 75 mcg tablets. |
| Jul 18, 2012 | Abbott Laboratories Defective Container: A number of Synthroid bottles have a localized thin wall defect on the bottom which may potentially impact the stability of the tablets. |
← Back to Levothyroxine Sodium
Sources: CMS Medicare Part D Prescribers 2024; CMS Open Payments 2025 (general payments; a payment is not evidence of wrongdoing); FDA enforcement reports (openFDA).